BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147-1161. [PMID: 18762933 DOI: 10.1007/s00228-008-0553-z] [Cited by in Crossref: 375] [Cited by in F6Publishing: 301] [Article Influence: 26.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim H, Long-boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, Jacobson P, Brundage R. Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. The Journal of Clinical Pharmacology 2012;52:1665-75. [DOI: 10.1177/0091270011422814] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
2 Mittal K, Wood LS, Rini BI. Axitinib in Metastatic Renal Cell Carcinoma. Biol Ther 2012;2:5. [PMID: 24392298 DOI: 10.1007/s13554-012-0005-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
3 Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. J Gastroenterol Hepatol. 2014;29:1356-1360. [PMID: 24548074 DOI: 10.1111/jgh.12560] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
4 Salem AH, Dave N, Marbury T, Hu B, Miles D, Agarwal SK, Bueno OF, Menon RM. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clin Pharmacokinet 2019;58:1091-100. [PMID: 30949874 DOI: 10.1007/s40262-019-00746-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010;4:1164-1173. [PMID: 20920436 DOI: 10.1177/193229681000400515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
6 Malik MY, Jaiswal S, Sharma A, Shukla M, Lal J. Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metab Rev 2016;48:281-327. [PMID: 26987379 DOI: 10.3109/03602532.2016.1157600] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
7 Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85:451-458. [PMID: 20357277 DOI: 10.4065/mcp.2009.0534] [Cited by in Crossref: 160] [Cited by in F6Publishing: 104] [Article Influence: 13.3] [Reference Citation Analysis]
8 Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-73. [PMID: 19543887 DOI: 10.1007/s00228-009-0678-8] [Cited by in Crossref: 173] [Cited by in F6Publishing: 129] [Article Influence: 13.3] [Reference Citation Analysis]
9 Cheeti S, Deng Y, Chang I, Georgescu I, Templeton I, Choong N, Cheung KWK, Girish S, Musib L. Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics. Clin Pharmacol Drug Dev 2021;10:144-52. [PMID: 32696585 DOI: 10.1002/cpdd.847] [Reference Citation Analysis]
10 Gabra BH, Abidi MH, Al-khadimi Z, Edwards DJ, Ibrahim RB. Systemic absorption of topical lidocaine in a bone marrow transplant recipient with hepatic sinusoidal obstruction syndrome. American Journal of Health-System Pharmacy 2011;68:135-7. [DOI: 10.2146/ajhp100026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141:1327-1336. [PMID: 22553267 DOI: 10.1378/chest.11-1396] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 13.0] [Reference Citation Analysis]
12 Zoratti C, Moretti R, Rebuzzi L, Albergati IV, Di Somma A, Decorti G, Di Bella S, Crocè LS, Giuffrè M. Antibiotics and Liver Cirrhosis: What the Physicians Need to Know. Antibiotics (Basel) 2021;11:31. [PMID: 35052907 DOI: 10.3390/antibiotics11010031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Barau C, Braun J, Vincent C, Haim-boukobza S, Molina J, Miailhes P, Fournier I, Aboulker J, Vittecoq D, Duclos-vallée J, Taburet A, Teicher E, Teicher E, Duclos-vallée J, Aboulker J, Braun J, Fournier I, Vincent C, Arulananthan A, Eliette V, Euphrasie F, Guillon B, Ralaimazava P, Haïm-boukobza S, Roque-afonso A, Bonhomme-faivre L, Rudant E, Taburet A, Aboulker J, Bonhomme-faivre L, Braun J, Couffin-cadiergues S, Delaugerre C, Durand F, Vittecoq D, Flandre P, Garraffo R, Ghosn J, Marraud A, Pageaux G, Derradji O, Bolliot C, Churaqui F, Antonini T, Coilly A, Ichai P, Ogier O, Belnard M, Molina J, De Lastours V, Gazaignes S, Ponscarme D, Sauvageon H, Miailhes P, Koffi J, Radenne S, Brochier C. Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study. Clinical Infectious Diseases 2014;59:1177-84. [DOI: 10.1093/cid/ciu515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
14 Stewart CA, Auger RR, Enders FT, Felmlee-Devine D, Smith GE. The effects of poor sleep quality on cognitive function of patients with cirrhosis. J Clin Sleep Med 2014;10:21-6. [PMID: 24426816 DOI: 10.5664/jcsm.3350] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
15 Kurata Y, Muraki S, Kashihara Y, Hirota T, Araki H, Ieiri I. Differences in Theophylline Clearance Between Patients With Chronic Hepatitis and Those With Liver Cirrhosis. Ther Drug Monit 2020;42:829-34. [PMID: 32657910 DOI: 10.1097/FTD.0000000000000787] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Neavyn MJ, Stolbach A, Greer DM, Nelson LS, Smith SW, Brent J, Tormoehlen LM; American College of Medical Toxicology. ACMT Position Statement: Determining Brain Death in Adults After Drug Overdose. J Med Toxicol 2017;13:271-3. [PMID: 28255927 DOI: 10.1007/s13181-017-0606-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
17 Kleiber N, Tromp K, Mooij MG, van de Vathorst S, Tibboel D, de Wildt SN. Ethics of drug research in the pediatric intensive care unit. Paediatr Drugs 2015;17:43-53. [PMID: 25354987 DOI: 10.1007/s40272-014-0101-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
18 Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. Journal of Pharmacy and Pharmacology 2013;65:1518-25. [DOI: 10.1111/jphp.12124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Lammers LA, Achterbergh R, Romijn JA, Mathôt RAA. Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role? Eur J Drug Metab Pharmacokinet 2018;43:251-7. [PMID: 28929443 DOI: 10.1007/s13318-017-0437-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
20 Chattopadhyay N, Riecke K, Ligges S, Zimmermann T, Halabi A, Schultze-Mosgau MH. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. Br J Clin Pharmacol 2019;85:2011-21. [PMID: 31112623 DOI: 10.1111/bcp.13992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
22 Ramón Azanza J, García E, Sádaba B, Manubens A. Uso de antimicrobianos en pacientes con insuficiencia renal o hepática. Enfermedades Infecciosas y Microbiología Clínica 2009;27:593-9. [DOI: 10.1016/j.eimc.2009.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Xie F, Vermeulen A, Colin P, Cheng Z. A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers. Br J Clin Pharmacol 2019;85:1003-14. [PMID: 30761579 DOI: 10.1111/bcp.13902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol 2019;75:1047-58. [PMID: 31079169 DOI: 10.1007/s00228-019-02688-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
25 Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol. 2013;53:463-474. [PMID: 23436293 DOI: 10.1002/jcph.23] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
26 Devarbhavi H, Choudhury AK, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Chawla YK, Dhiman RK, Duseja A, Taneja S, Ning Q, Jia JD, Duan Z, Yu C, Eapen CE, Goel A, Tan SS, Hamid SS, Butt AS, Jafri W, Kim DJ, Hu J, Sood A, Midha V, Shukla A, Ghazinian H, Sahu MK, Treeprasertsuk S, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Kalal C, Abbas Z, Sollano JD, Prasad VGM, Payawal DA, Dokmeci AK, Rao PN, Shrestha A, Lau GK, Yuen MF, Saraswat VA, Shiha G, Yokosuka O, Kedarisetty CK, Jain P, Bhatia P, Sarin SK; APASL ACLF working party. Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. Am J Gastroenterol. 2019;114:929-937. [PMID: 31021832 DOI: 10.14309/ajg.0000000000000201] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
27 del Mar Fernández de Gatta M, Martin-Suarez A, Lanao JM. Approaches for dosage individualisation in critically ill patients. Expert Opin Drug Metab Toxicol 2013;9:1481-93. [PMID: 23898816 DOI: 10.1517/17425255.2013.822486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
28 Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol 2013;53:962-6. [PMID: 23832278 DOI: 10.1002/jcph.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
29 Rocha JF, Santos A, Falcão A, Lopes N, Nunes T, Pinto R, Soares-da-Silva P. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol 2014;70:279-86. [PMID: 24271646 DOI: 10.1007/s00228-013-1602-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
30 Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med. 2014;17:1271-1277. [PMID: 25390468 DOI: 10.1089/jpm.2013.0167] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 9.6] [Reference Citation Analysis]
31 Spanakis M, Patelarou AE, Patelarou E. Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice. J Pers Med 2020;10:E56. [PMID: 32610469 DOI: 10.3390/jpm10030056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fung BM, Leon DJ, Beck LN, Tabibian JH. Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease. Dig Dis Sci 2021. [PMID: 34169430 DOI: 10.1007/s10620-021-07111-1] [Reference Citation Analysis]
33 Klinge M, Coppler T, Liebschutz JM, Dugum M, Wassan A, DiMartini A, Rogal S. The assessment and management of pain in cirrhosis. Curr Hepatol Rep 2018;17:42-51. [PMID: 29552453 DOI: 10.1007/s11901-018-0389-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
34 De Bock L, Colin P, Boussery K, Van Bocxlaer J. Development and validation of an enzyme-linked immunosorbent assay for the quantification of cytochrome 3A4 in human liver microsomes. Talanta 2012;99:357-62. [DOI: 10.1016/j.talanta.2012.05.064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Zhao D, Chen J, Chu M, Long X, Wang J. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. Drug Des Devel Ther 2020;14:1663-81. [PMID: 32431491 DOI: 10.2147/DDDT.S249098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J, Molz K. Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment: . Clinical Pharmacokinetics 2010;49:607-18. [DOI: 10.2165/11534330-000000000-00000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
37 Almansour MI, Jarrar YB, Jarrar BM. In vivo investigation on the chronic hepatotoxicity induced by sertraline. Environmental Toxicology and Pharmacology 2018;61:107-15. [DOI: 10.1016/j.etap.2018.05.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
38 Floreani M, De Martin S, Gabbia D, Barbierato M, Nassi A, Mescoli C, Orlando R, Bova S, Angeli P, Gola E. Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes. PLoS One. 2013;8:e61983. [PMID: 23626760 DOI: 10.1371/journal.pone.0061983;] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Tan Y, Hu Y, Liu X, Yin Z, Chen XW, Liu M. Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation. Methods 2016;110:14-25. [PMID: 27485605 DOI: 10.1016/j.ymeth.2016.07.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
40 Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol 2016; 22(3): 1260-1278 [PMID: 26811663 DOI: 10.3748/wjg.v22.i3.1260] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
41 Liu H, Yu Y, Guo N, Wang X, Han B, Xiang X. Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib. Front Pharmacol 2021;12:780937. [PMID: 34880763 DOI: 10.3389/fphar.2021.780937] [Reference Citation Analysis]
42 Riepe MW, Walther B, Vonend C, Beer AJ. Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study. BMC Psychiatry 2015;15:157. [PMID: 26163145 DOI: 10.1186/s12888-015-0531-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Marcinak J, Vakilynejad M, Kogame A, Tagawa Y. Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment. Drugs R D 2018;18:109-18. [PMID: 29488154 DOI: 10.1007/s40268-018-0229-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Palatini P, Orlando R, De Martin S. The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opinion on Drug Metabolism & Toxicology 2010;6:1215-30. [DOI: 10.1517/17425255.2010.503704] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
45 Zhang W, Krauwinkel WJ, Keirns J, Townsend RW, Lasseter KC, Plumb L, Kadokura T, Ushigome F, Smulders R. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. Clin Drug Investig. 2013;33:489-496. [PMID: 23733389 DOI: 10.1007/s40261-013-0089-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
46 Yoshida K, Maeda K, Kusuhara H, Konagaya A. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. BMC Syst Biol 2013;7 Suppl 3:S3. [PMID: 24555857 DOI: 10.1186/1752-0509-7-S3-S3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
47 Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, Monster-Simons MH, van Putten SA, Metselaar HJ, Taxis K, Borgsteede SD. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open 2016;6:e012991. [PMID: 27733414 DOI: 10.1136/bmjopen-2016-012991] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
48 Jun H, Rong Y, Yih C, Ho J, Cheng W, Kiang TKL. Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling. Drugs R D 2020;20:343-58. [PMID: 33026608 DOI: 10.1007/s40268-020-00323-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Hollebecque A, Postel-vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria J. Modifying phase I methodology to facilitate enrolment of molecularly selected patients. European Journal of Cancer 2013;49:1515-20. [DOI: 10.1016/j.ejca.2012.12.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
50 Edelson JC, Rockey DC. Endoscopic Sedation of the Patient With Cirrhosis. Clin Liver Dis (Hoboken). 2018;12:165-169. [PMID: 30988936 DOI: 10.1002/cld.762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Hilscher MB, Odell LJ, Myhre LJ, Prokop L, Talwalkar J. The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions. J Clin Pharm Ther 2016;41:587-91. [PMID: 27576303 DOI: 10.1111/jcpt.12443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
52 Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, Ganten TM, Sauer P, Haefeli WE. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2014;77:160-169. [PMID: 23772874 DOI: 10.1111/bcp.12182] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
53 Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet 2015;54:457-71. [PMID: 25860376 DOI: 10.1007/s40262-015-0255-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
54 Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf. 2016;39:729-744. [PMID: 27091053 DOI: 10.1007/s40264-016-0423-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
55 Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, Zhu L, Wang X, Dong Y. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study. Int J Infect Dis. 2018;72:49-54. [PMID: 29793038 DOI: 10.1016/j.ijid.2018.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
56 Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JP, Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism & Toxicology 2020;16:45-57. [DOI: 10.1080/17425255.2020.1702022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
57 Volk BM, Creighton BC. An Overview on Caffeine. Nutrition and Enhanced Sports Performance. Elsevier; 2013. pp. 487-95. [DOI: 10.1016/b978-0-12-396454-0.00051-5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
58 Chikhani M, Hardman JG. Pharmacokinetic variation. Anaesthesia & Intensive Care Medicine 2016;17:163-5. [DOI: 10.1016/j.mpaic.2015.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Saeheng T, Na-Bangchang K, Karbwang J. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. Eur J Clin Pharmacol 2018;74:1365-76. [PMID: 29978293 DOI: 10.1007/s00228-018-2513-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Angamo MT, Curtain CM, Chalmers L, Yilma D, Bereznicki L. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study. PLoS One 2017;12:e0186631. [PMID: 29036230 DOI: 10.1371/journal.pone.0186631] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
61 Candelli M, Pompili M, Suppressa P, Lenato GM, Bosco G, Rapaccini GL, Gasbarrini A, Scardapane A, Sabbà C. Liver involvement in hereditary hemorrhagic telangiectasia: can breath test unmask impaired hepatic first-pass effect? Intern Emerg Med 2012;7:323-9. [DOI: 10.1007/s11739-011-0531-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
62 Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment. Antimicrob Agents Chemother 2016;60:3025-31. [PMID: 26953193 DOI: 10.1128/AAC.02942-15] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
63 Golla K, Mannell H, Benesic A, Dreischulte T, Grill E, Strobach D. Feasibility of the MELD score as a screening tool for pharmacists to identify patients with impaired hepatic function at hospital admission. J Clin Pharm Ther 2022. [PMID: 35014073 DOI: 10.1111/jcpt.13597] [Reference Citation Analysis]
64 Martin P, Oliver S, Gillen M, Marbury T, Millson D. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clin Ther 2015;37:2823-36. [PMID: 26519231 DOI: 10.1016/j.clinthera.2015.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Horiuchi A, Graham DY. Special topics in procedural sedation: clinical challenges and psychomotor recovery. Gastrointest Endosc. 2014;80:404-409. [PMID: 24981806 DOI: 10.1016/j.gie.2014.04.063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
66 Wong M, Busuttil RW. Surgery in Patients with Portal Hypertension. Clin Liver Dis. 2019;23:755-780. [PMID: 31563221 DOI: 10.1016/j.cld.2019.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
67 Curran A, Martí R, López RM, Pérez M, Crespo M, Melià MJ, Navarro J, Burgos J, Falcó V, Ocaña I, Ribera E. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients. Antimicrob Agents Chemother 2015;59:6782-90. [PMID: 26282411 DOI: 10.1128/AAC.01099-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Avigan MI, Muñoz MA. Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI). In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 367-93. [DOI: 10.1007/978-1-4939-7677-5_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, van Gelder T, Mathot RA. Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. Clin Pharmacokinet 2016;55:697-709. [PMID: 26715216 DOI: 10.1007/s40262-015-0345-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
70 Chen J, Zhang X, Luo H, Wu C, Yu M, Liu D, Xi H, Zhou Y, An Y, Xu X. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. Oncotarget 2017;8:90916-24. [PMID: 29207613 DOI: 10.18632/oncotarget.18701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
71 Bruderer S, Detishin V, Tsvitbaum N, Dingemanse J. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. Br J Clin Pharmacol 2011;71:52-60. [PMID: 21143501 DOI: 10.1111/j.1365-2125.2010.03804.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
72 Stravitz RT, Ilan Y. Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? Liver Int 2017;37:328-36. [DOI: 10.1111/liv.13268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Lammers LA, Achterbergh R, van Schaik RHN, Romijn JA, Mathôt RAA. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clin Pharmacokinet 2017;56:1231-44. [PMID: 28229374 DOI: 10.1007/s40262-017-0515-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
74 Zhai J, Zhang F, Gao S, Chen L, Feng G, Yin J, Chen W. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats. Molecules 2017;22:E1298. [PMID: 28786954 DOI: 10.3390/molecules22081298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
75 Miranda P, Corvetto MA, Altermatt FR, Araneda A, Echevarría GC, Cortínez LI. Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. Eur J Clin Pharmacol 2016;72:1221-7. [PMID: 27417947 DOI: 10.1007/s00228-016-2086-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
76 Khoury T, Rmeileh AA, Yosha L, Benson AA, Daher S, Mizrahi M. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol 2015;3:99-108. [PMID: 26356634 DOI: 10.14218/JCTH.2015.00007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
77 Rasool MF, Khalid S, Majeed A, Saeed H, Imran I, Mohany M, Al-Rejaie SS, Alqahtani F. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations. Pharmaceutics 2019;11:E578. [PMID: 31694244 DOI: 10.3390/pharmaceutics11110578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
78 Shouval D. Focus. J Hepatol 2011;54:597-8. [PMID: 21167854 DOI: 10.1016/j.jhep.2010.12.006] [Reference Citation Analysis]
79 Mahar KM, Shaddinger BC, Ramanjineyulu B, Andrews S, Caltabiano S, Lindsay AC, Cobitz AR. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function. Clin Pharmacol Drug Dev 2022. [PMID: 35355447 DOI: 10.1002/cpdd.1090] [Reference Citation Analysis]
80 De Martin S, Gabbia D, Albertin G, Sfriso MM, Mescoli C, Albertoni L, Paliuri G, Bova S, Palatini P. Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. Drug Metab Dispos. 2014;42:1617-1626. [PMID: 25030308 DOI: 10.1124/dmd.114.058511] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
81 Çelebi N, Muğlalı M, Aksoy A, Yarım G, Yarım M, Güvenç D. Comparison of lidocaine metabolism for different anesthesia techniques in rabbits with liver disease. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:e23-6. [PMID: 22819454 DOI: 10.1016/j.oooo.2011.11.026] [Reference Citation Analysis]
82 McCain JD, Stancampiano FF, Bouras EP, DeVault KR, Gilbert EL, Ryan T, Maillis A, Heckman MG, Diehl NN, Palmer WC. Creation of a score to predict risk of high conscious sedation requirements in patients undergoing endoscopy. Gastrointest Endosc 2020; 91: 595-605. e3. [PMID: 31756314 DOI: 10.1016/j.gie.2019.11.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Nakamaru Y, Kakubari M, Yoshida K, Akimoto M, Todorovic V, Greis T, Kondo K. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Clin Ther 2020;42:1467-1482.e4. [PMID: 32800532 DOI: 10.1016/j.clinthera.2020.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Bartoletti M, Giannella M, Tedeschi S, Viale P. Opportunistic infections in end stage liver disease. Infect Dis Rep 2018;10:7621. [PMID: 29721243 DOI: 10.4081/idr.2018.7621] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
85 Phelan M, Anzures-cabrera J, Carlile DJ, Rowell L, Kuhlmann O, Arold G, Robson R, Bentley D. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib: Altered Distribution of the Active Thiol? Clin Pharmacokinet 2013;52:255-65. [DOI: 10.1007/s40262-013-0035-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
86 Carrion AF, Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. Expert Opinion on Drug Safety 2016;15:883-90. [DOI: 10.1080/14740338.2016.1179278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
87 Miyata A, Hasegawa M, Hachiuma K, Mori H, Horiuchi N, Mizuno-yasuhira A, Chino Y, Jingu S, Sakai S, Samukawa Y, Nakai Y, Yamaguchi J. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans. Xenobiotica 2017;47:332-45. [DOI: 10.1080/00498254.2016.1193263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
88 Sidharta PN, Lindegger N, Ulč I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol 2014;54:291-300. [PMID: 24122797 DOI: 10.1002/jcph.193] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
89 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 141] [Cited by in F6Publishing: 128] [Article Influence: 70.5] [Reference Citation Analysis]
90 Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, Winston B, Redd J, Ready J, Terrault NA. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology 2015;62:715-25. [PMID: 26033798 DOI: 10.1002/hep.27922] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 12.1] [Reference Citation Analysis]
91 Zhang M, You X, Ke M, Jiao Z, Wu H, Huang P, Lin C. Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. J Pharm Sci 2019;108:2781-90. [PMID: 30928308 DOI: 10.1016/j.xphs.2019.03.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
92 Weersink RA, Abadier M, de Boer A, Taxis K, Borgsteede SD. Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. Br J Clin Pharmacol 2020;86:763-70. [PMID: 31756269 DOI: 10.1111/bcp.14177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Dietrich CG, Götze O, Geier A. Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol 2016; 22(1): 72-88 [PMID: 26755861 DOI: 10.3748/wjg.v22.i1.72] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
94 Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:773-785. [PMID: 25091053 DOI: 10.1007/s40262-014-0157-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
95 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012;35:1099-1117. [PMID: 23137150 DOI: 10.2165/11632970-000000000-00000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, Somasunderam A, Utay NS. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. Clin Transl Sci. 2016;9:139-148. [PMID: 27169903 DOI: 10.1111/cts.12397] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
97 El-Khateeb E, Al-Majdoub ZM, Rostami-Hodjegan A, Barber J, Achour B. Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. Drug Metab Dispos 2021;49:610-8. [PMID: 34045218 DOI: 10.1124/dmd.121.000484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Zhao Y, Hou J, Xiao Y, Wang F, Zhang B, Zhang M, Jiang Y, Li J, Gong G, Xiang D, Yan M. Predictors of Voriconazole Trough Concentrations in Patients with Child-Pugh Class C Cirrhosis: A Prospective Study. Antibiotics (Basel) 2021;10:1130. [PMID: 34572712 DOI: 10.3390/antibiotics10091130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Schultalbers M, Grote-Koska D, Cornberg M, Schmidt JJ, Maasoumy B; CirPK - Study Group. Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2021:S0168-8278(21)01914-0. [PMID: 34310999 DOI: 10.1016/j.jhep.2021.07.015] [Reference Citation Analysis]
100 Tang D, Yan M, Song BL, Zhao YC, Xiao YW, Wang F, Liang W, Zhang BK, Chen XJ, Zou JJ, Tian Y, Wang WL, Jiang YF, Gong GZ, Zhang M, Xiang DX. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study. Br J Clin Pharmacol 2021;87:1890-902. [PMID: 33010043 DOI: 10.1111/bcp.14578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
101 Bastida C, Hernández-Tejero M, Aziz F, Espinosa C, Sanz M, Brunet M, López E, Fernández J, Soy D. Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections. J Antimicrob Chemother 2020;75:3619-24. [PMID: 32887993 DOI: 10.1093/jac/dkaa362] [Reference Citation Analysis]
102 El-demerdash E, Abdel-sattar SA, El-bakly WM, Mohamed EA. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. Eur J Drug Metab Pharmacokinet 2017;42:767-79. [DOI: 10.1007/s13318-016-0391-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
103 Zgheib NK, Branch RA. Drug metabolism and liver disease: a drug-gene-environment interaction. Drug Metab Rev 2017;49:35-55. [PMID: 27957864 DOI: 10.1080/03602532.2016.1271807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
104 Krystallis C, Masterton GS, Hayes PC, Plevris JN. Update of endoscopy in liver disease: More than just treating varices. World J Gastroenterol 2012; 18(5): 401-411 [PMID: 22346246 DOI: 10.3748/wjg.v18.i5.401] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
105 Pena M, Horga J, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Review of Clinical Pharmacology 2015;9:441-58. [DOI: 10.1586/17512433.2016.1135733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
106 Weersink RA, Drenth JP, Borgsteede SD. Why zolpidem increases the risk of falls and fractures in patients with cirrhosis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100528] [Reference Citation Analysis]
107 Liu Z, Qu Z, Li X, Cai M, He P, Zhou M, Xiao J, Wang X. Phenacetin O-deethylation is a useful tool for evaluation of hepatic functional reserve in rats with CCl(4)-induced chronic liver injury. J Surg Res 2012;175:e61-6. [PMID: 22341342 DOI: 10.1016/j.jss.2011.11.1037] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Le Vee M, Jouan E, Stieger B, Lecureur V, Fardel O. Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochemical Pharmacology 2011;82:304-11. [DOI: 10.1016/j.bcp.2011.04.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
109 Storelli F, Samer C, Reny JL, Desmeules J, Daali Y. Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. Clin Pharmacokinet. 2018;57:1267-1293. [PMID: 29667038 DOI: 10.1007/s40262-018-0650-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
110 Saab S, Konyn PG, Viramontes MR, Jimenez MA, Grotts JF, Hamidzadah W, Dang VP, Esmailzadeh NL, Choi G, Durazo FA, El-Kabany MM, Han SB, Tong MJ. Limited Knowledge of Acetaminophen in Patients with Liver Disease. J Clin Transl Hepatol 2016;4:281-7. [PMID: 28097095 DOI: 10.14218/JCTH.2016.00049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
111 Siccardi M, Rajoli RKR, Curley P, Olagunju A, Moss D, Owen A. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology 2013;8:871-90. [DOI: 10.2217/fvl.13.67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
112 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current Challenges and Controversies in Drug-Induced Liver Injury. Drug Saf 2012;35:1099-117. [DOI: 10.1007/bf03261997] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
113 Lee SJ, Lee YJ, Park KK. The pathogenesis of drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2016;10:1175-85. [PMID: 27248313 DOI: 10.1080/17474124.2016.1196133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
114 Le Daré B, Ferron PJ, Gicquel T. [Once upon a time the hepatotoxicity…]. Med Sci (Paris) 2021;37:235-41. [PMID: 33739270 DOI: 10.1051/medsci/2021009] [Reference Citation Analysis]
115 Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel. Clin Transl Sci 2022. [PMID: 35583936 DOI: 10.1111/cts.13298] [Reference Citation Analysis]
116 Sethi P, Bruckner JV, Mortuza TB, Cummings BS, Muralidhara S, White CA. Plasma Protein and Lipoprotein Binding of Cis - and Trans -Permethrin and Deltamethrin in Adult Humans and Rats. Drug Metab Dispos 2019;47:941-8. [DOI: 10.1124/dmd.118.085464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Rasool MF, Khalil F, Läer S. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. Eur J Drug Metab Pharmacokinet 2017;42:383-96. [DOI: 10.1007/s13318-016-0353-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
118 He R, Li Y, Ruan J. Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation. Med Sci Monit 2015;21:396-402. [PMID: 25648948 DOI: 10.12659/MSM.892044] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
119 Wood T, Thoresen M. Physiological responses to hypothermia. Semin Fetal Neonatal Med 2015;20:87-96. [PMID: 25457082 DOI: 10.1016/j.siny.2014.10.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
120 De Bock L, Boussery K, Colin P, De Smet J, T’jollyn H, Van Bocxlaer J. Development and validation of a fast and sensitive UPLC–MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta 2012;89:209-16. [DOI: 10.1016/j.talanta.2011.11.083] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
121 Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 2013;53:633-41. [PMID: 23649964 DOI: 10.1002/jcph.82] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
122 Kim CO, Lee HW, Oh ES, Seong SJ, Kim DY, Lee J, Ahn S, Yoon Y, Cho C, Park MS. Influence of Hepatic Dysfunction on the Pharmacokinetics and Safety of Fimasartan: . Journal of Cardiovascular Pharmacology 2013;62:524-9. [DOI: 10.1097/fjc.0000000000000010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
123 Larson AM. Palliative Care for Patients with End-Stage Liver Disease. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0440-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
124 Montanha MC, Cottura N, Booth M, Hodge D, Bunglawala F, Kinvig H, Grañana-castillo S, Lloyd A, Khoo S, Siccardi M. PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. Front Pharmacol 2022;13:814134. [DOI: 10.3389/fphar.2022.814134] [Reference Citation Analysis]
125 Bertera F, Di Verniero CA, Mayer MA, Chiappetta D, Buontempo F, Polizio AH, Taira CA, Höcht C. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats. Xenobiotica 2011;42:206-19. [DOI: 10.3109/00498254.2011.604746] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
126 Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. Clin Pharmacol Drug Dev 2016;5:141-9. [PMID: 27138027 DOI: 10.1002/cpdd.238] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
127 Feng L, Mao W, Zhang J, Liu X, Jiao Y, Zhao X, Wang X, Zhang D, Cai D, Wang Y. Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects. Drug Development and Industrial Pharmacy 2013;40:1-8. [DOI: 10.3109/03639045.2012.756513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
128 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
129 Stanczyk FZ, Burke AE, Hong KM, Archer DF. Morbid obesity: potential effects of hormonal contraception. Contraception 2018;98:174-80. [PMID: 29777662 DOI: 10.1016/j.contraception.2018.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
130 Moschny N, Hefner G, Grohmann R, Eckermann G, Maier HB, Seifert J, Heck J, Francis F, Bleich S, Toto S, Meissner C. Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics. Pharmaceuticals (Basel) 2021;14:514. [PMID: 34071813 DOI: 10.3390/ph14060514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Haahr H, Heise T. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clin Pharmacokinet 2020;59:155-72. [PMID: 31667789 DOI: 10.1007/s40262-019-00834-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
132 Abdulatif M, Lotfy M, Mousa M, Afifi MH, Yassen K. Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. Minerva Anestesiol 2018;84. [DOI: 10.23736/s0375-9393.18.12217-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
133 Kosugi Y, Hosea N. Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. Mol Pharm 2020;17:2299-309. [PMID: 32478525 DOI: 10.1021/acs.molpharmaceut.9b01294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
134 Chen Y, Ke M, Xu J, Lin C. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. AAPS PharmSciTech 2020;21:98. [PMID: 32128656 DOI: 10.1208/s12249-020-1638-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
135 De Winter S, Verelst S, Wauters J, Van der Linden L, Verslype C, Willems L, Spriet I. Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt. Eur J Clin Pharmacol 2014;70:377-8. [DOI: 10.1007/s00228-013-1629-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
136 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806-1820. [PMID: 29688583 DOI: 10.1111/bcp.13615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
137 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
138 García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Maldonado-Garza HJ, Villarreal-Pérez JZ. The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol. 2015;14:780-788. [PMID: 26436350 DOI: 10.5604/16652681.1171746] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
139 Deleenheer B, Spriet I, Maertens J. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 2018;14:1197-207. [PMID: 30479172 DOI: 10.1080/17425255.2018.1550485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
140 Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189-206. [PMID: 20170207 DOI: 10.2165/11318160-000000000-00000] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 10.3] [Reference Citation Analysis]
141 Laurenza A, Yang H, Williams B, Zhou S, Ferry J. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies. Epilepsy Research 2015;113:76-85. [DOI: 10.1016/j.eplepsyres.2015.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
142 Ojeda A, Moreno LA. Pain management in patients with liver cirrhosis. Gastroenterol Hepatol. 2014;37:35-45. [PMID: 24309482 DOI: 10.1016/j.gastrohep.2013.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
143 Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clin Pharmacokinet 2015;54:837-49. [PMID: 25603822 DOI: 10.1007/s40262-015-0238-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
144 Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Review of Clinical Pharmacology 2017;10:965-81. [DOI: 10.1080/17512433.2017.1345623] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
145 Small DS, Farid NA, Li YG, Ernest Ii CS, Winters KJ, Salazar DE, Payne CD. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. Journal of Clinical Pharmacy and Therapeutics 2009;34:575-83. [DOI: 10.1111/j.1365-2710.2009.01067.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
146 Hirano M, Meyers D, Golla G, Pal P, Pinot P, Lin T, Majumdar T, Rebello S, Sunkara G, Chen J. Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor. Clin Pharmacokinet 2015;54:761-70. [DOI: 10.1007/s40262-015-0235-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
147 Hamed SS, Al-Yhya NA, El-Khadragy MF, Al-Olayan EM, Alajmi RA, Hassan ZK, Hassan SB, Abdel Moneim AE. The Protective Properties of the Strawberry (Fragaria ananassa) against Carbon Tetrachloride-Induced Hepatotoxicity in Rats Mediated by Anti-Apoptotic and Upregulation of Antioxidant Genes Expression Effects. Front Physiol 2016;7:325. [PMID: 27547187 DOI: 10.3389/fphys.2016.00325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
148 Butler K, Teng R. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment. The Journal of Clinical Pharmacology 2011;51:978-87. [DOI: 10.1177/0091270010379409] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
149 Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014;77:3-11. [PMID: 25038549 DOI: 10.1016/j.addr.2014.07.006] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 31.3] [Reference Citation Analysis]
150 Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. J Clin Pharmacol 2017;57:777-83. [PMID: 28026013 DOI: 10.1002/jcph.857] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
151 Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 2019;20:e200-7. [PMID: 30942181 DOI: 10.1016/S1470-2045(19)30145-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
152 Ma Y, Xin M, Wen Y, Wang H, Zhang G, Dai J, Wu XA. The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats. Asian J Pharm Sci 2021;16:519-29. [PMID: 34703500 DOI: 10.1016/j.ajps.2021.03.002] [Reference Citation Analysis]
153 Clarke JD, Cherrington NJ. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol 2012;8:349-60. [PMID: 22280100 DOI: 10.1517/17425255.2012.656087] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
154 Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009;15:2960-74. [PMID: 19554648 DOI: 10.3748/wjg.15.2960] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
155 Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharm Res 2022. [PMID: 35552967 DOI: 10.1007/s11095-022-03274-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Harris DG. Management of pain in advanced disease. British Medical Bulletin 2014;110:117-28. [DOI: 10.1093/bmb/ldu010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
157 Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J Pharmacol Exp Ther. 2014;348:452-458. [PMID: 24403518 DOI: 10.1124/jpet.113.211284] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
158 Floreani M, De Martin S, Gabbia D, Barbierato M, Nassi A, Mescoli C, Orlando R, Bova S, Angeli P, Gola E. Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes. PLoS One. 2013;8:e61983. [PMID: 23626760 DOI: 10.1371/journal.pone.0061983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
159 Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther 2014;36:1016-1027.e2. [PMID: 24947493 DOI: 10.1016/j.clinthera.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
160 Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. Br J Clin Pharmacol 2021;87:4013-9. [PMID: 33738827 DOI: 10.1111/bcp.14829] [Reference Citation Analysis]
161 Fagiuoli S, Colli A, Bruno R, Burra P, Craxì A, Gaeta GB, Grossi P, Mondelli MU, Puoti M, Sagnelli E, Stefani S, Toniutto P. Management of infections in cirrhotic patients: Report of a Consensus Conference. Digestive and Liver Disease 2014;46:204-12. [DOI: 10.1016/j.dld.2013.07.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
162 Bartoletti M, Lewis RE, Giannella M, Tedeschi S, Viale P. The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis. Expert Review of Anti-infective Therapy 2018;16:771-9. [DOI: 10.1080/14787210.2018.1523716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Lin L, Tian L, Li T, Sun M, Duan J, Yu Y, Sun Z. Microarray analysis of mRNA expression profiles in liver of ob/ob mice with real-time atmospheric PM2.5 exposure. Environ Sci Pollut Res. [DOI: 10.1007/s11356-022-21088-y] [Reference Citation Analysis]
164 Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N, Yu L. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib. J Clin Pharmacol 2018;58:1618-28. [PMID: 30052269 DOI: 10.1002/jcph.1286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
165 Park J, Kim CO, Oh ES, Lee JI, Kim JK, Ahn SH, Kim DY, Kim SU, Kim BK, Chung YE, Kim SM, Park MS. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. Clin Pharmacol Drug Dev 2022. [PMID: 35255191 DOI: 10.1002/cpdd.1045] [Reference Citation Analysis]
166 Lee KW, Chan SL. Hepatotoxicity of targeted therapy for cancer. Expert Opin Drug Metab Toxicol 2016;12:789-802. [PMID: 27187715 DOI: 10.1080/17425255.2016.1190831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
167 Nanchal R, Subramanian R, Karvellas CJ, Hollenberg SM, Peppard WJ, Singbartl K, Truwit J, Al-khafaji AH, Killian AJ, Alquraini M, Alshammari K, Alshamsi F, Belley-cote E, Cartin-ceba R, Dionne JC, Galusca DM, Huang DT, Hyzy RC, Junek M, Kandiah P, Kumar G, Morgan RL, Morris PE, Olson JC, Sieracki R, Steadman R, Taylor B, Alhazzani W. Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations. Critical Care Medicine 2020;48:e173-91. [DOI: 10.1097/ccm.0000000000004192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
168 Aboel Dahab A, El-hag D, Moutamed GM, Aboel Dahab S, Abuknesha R, Smith NW. Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics. Cancer Chemother Pharmacol 2016;78:465-89. [DOI: 10.1007/s00280-016-3028-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
169 Dame K, Ribeiro AJ. Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects. Exp Biol Med (Maywood) 2021;246:317-31. [PMID: 32938227 DOI: 10.1177/1535370220959598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Lee ZY, Suah BH, Teo YH, Teo YN, Syn NLX, Yeo TC, Wong RCC, Chai P, Wong YJ, Ho JSY, Leow AS, Yeo LLL, Tan BYQ, Sia CH. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation and Concomitant Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2022;22:157-65. [PMID: 34008145 DOI: 10.1007/s40256-021-00482-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
171 Lin XB, Huang F, Tong L, Xia YZ, Wu JJ, Li J, Hu XG, Liang T, Liu XM, Zhong GP, Cai CJ, Chen X. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit. Int J Infect Dis 2020;93:345-52. [PMID: 32109625 DOI: 10.1016/j.ijid.2020.02.041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Yadesa TM, Kitutu FE, Deyno S, Ogwang PE, Tamukong R, Alele PE. Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis. SAGE Open Med 2021;9:20503121211039099. [PMID: 34422271 DOI: 10.1177/20503121211039099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Johnson-davis KL, Dasgupta A. Special Issues in Therapeutic Drug Monitoring in Patients With Uremia, Liver Disease, and in Critically Ill Patients. Clinical Challenges in Therapeutic Drug Monitoring. Elsevier; 2016. pp. 245-60. [DOI: 10.1016/b978-0-12-802025-8.00011-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
174 Peters FT, Steuer AE. Antemortem and postmortem influences on drug concentrations and metabolite patterns in postmortem specimens. WIREs Forensic Sci 2019;1. [DOI: 10.1002/wfs2.1297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Ingram K, Duthaler U, Vargas M, Ellis W, Keiser J. Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection. Antimicrob Agents Chemother 2013;57:4506-11. [PMID: 23836173 DOI: 10.1128/AAC.01129-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
176 Shen G, Gao H. Low-dose tolvaptan for the treatment of dilutional hyponatremia in cirrhosis: a case report and literature review. Case Reports Hepatol 2014;2014:795261. [PMID: 25383228 DOI: 10.1155/2014/795261] [Reference Citation Analysis]
177 de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-27. [PMID: 24723109 DOI: 10.1007/s40262-014-0142-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
178 Fitzpatrick RL, Quimby JM, Benson KK, Ramirez D, Sieberg LG, Wittenburg LA, Gustafson DL. In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. J Vet Intern Med 2018;32:1951-7. [PMID: 30307637 DOI: 10.1111/jvim.15237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
179 Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012;72:1645-1669. [PMID: 22867045 DOI: 10.2165/11635500-000000000-00000] [Cited by in Crossref: 95] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
180 Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2015;55:1395-405. [PMID: 26011596 DOI: 10.1002/jcph.550] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
181 Bϋdingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis 2014;2:17-42. [PMID: 24949199 DOI: 10.1177/2049936113519089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
182 Kosloski MP, Wang H, Pugatch D, Mensa FJ, Gane E, Lawitz E, Marbury TC, Preston RA, Kort J, Liu W. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. Eur J Clin Pharmacol 2019;75:217-26. [PMID: 30341499 DOI: 10.1007/s00228-018-2576-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
183 Noone J, Critchley E, Cullingham P, Coulthard P, Saksena A. The implications of substance misuse for intravenous conscious sedation practice. Br Dent J 2015;218:227-30. [PMID: 25720886 DOI: 10.1038/sj.bdj.2015.96] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Lammers LA, Achterbergh R, Romijn JA, Mathôt RAA. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. Eur J Drug Metab Pharmacokinet 2018;43:751-67. [PMID: 29876844 DOI: 10.1007/s13318-018-0487-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
185 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
186 Joshi A, Kiesel BF, Chaphekar N, Jones R, Guo J, Kunos CA, Taylor S, Chu E, Venkataramanan R, Beumer JH. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Cancer Chemother Pharmacol 2020;86:633-40. [PMID: 32989483 DOI: 10.1007/s00280-020-04154-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Weersink RA, Timmermans L, Monster-Simons MH, Mol PGM, Metselaar HJ, Borgsteede SD, Taxis K. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment. Front Pharmacol 2019;10:1031. [PMID: 31607904 DOI: 10.3389/fphar.2019.01031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
188 Malec M, Shega JW. Pain management in the elderly. Med Clin North Am 2015;99:337-50. [PMID: 25700587 DOI: 10.1016/j.mcna.2014.11.007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
189 Zaporowska-Stachowiak I, Szymański K, Oduah MT, Stachowiak-Szymczak K, Łuczak J, Sopata M. Midazolam: Safety of use in palliative care: A systematic critical review. Biomed Pharmacother 2019;114:108838. [PMID: 30981104 DOI: 10.1016/j.biopha.2019.108838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
190 Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon 2014;14:e23539. [PMID: 25477978 DOI: 10.5812/hepatmon.23539] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
191 Dewald TA, Washam JB, Becker RC. Anticoagulants. Neurosurgery Clinics of North America 2018;29:503-15. [DOI: 10.1016/j.nec.2018.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
192 Uney K, Tumer I, Traş B. Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. Xenobiotica 2011;41:585-92. [PMID: 21476905 DOI: 10.3109/00498254.2011.572199] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
193 Sharma R, Greenhough S, Medine CN, Hay DC. Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol. 2010;2010:236147. [PMID: 20169088 DOI: 10.1155/2010/236147] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
194 El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol 2016;9:1413-21. [PMID: 27603877 DOI: 10.1080/17512433.2016.1233813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
195 Badhan RK, Gittins R, Al Zabit D. The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. Drug and Alcohol Dependence 2019;200:168-80. [DOI: 10.1016/j.drugalcdep.2019.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
196 Niu L, Ding L, Lu C, Zuo F, Yao K, Xu S, Li W, Yang D, Xu X. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations. J Ethnopharmacol 2016;191:350-9. [PMID: 27318274 DOI: 10.1016/j.jep.2016.06.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
197 Kim BH, Park JW. Systemic therapy for hepatocellular carcinoma: why do we keep failing? Hepat Oncol 2014;1:355-8. [PMID: 30190969 DOI: 10.2217/hep.14.23] [Reference Citation Analysis]
198 Ostroumova OD, Pereverzev AP. Hepatic impairment as a risk factor of adverse drug reactions. Consilium Medicum 2021;23:939-48. [DOI: 10.26442/20751753.2021.12.201234] [Reference Citation Analysis]
199 Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K; ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res 2012;40:2381-93. [PMID: 23321196 DOI: 10.1177/030006051204000637] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
200 Samsky MD, Patel CB, Dewald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF. Cardiohepatic Interactions in Heart Failure. Journal of the American College of Cardiology 2013;61:2397-405. [DOI: 10.1016/j.jacc.2013.03.042] [Cited by in Crossref: 138] [Cited by in F6Publishing: 116] [Article Influence: 15.3] [Reference Citation Analysis]
201 Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016;39:589-611. [PMID: 27098247 DOI: 10.1007/s40264-016-0420-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
202 De Bock L, Boussery K, Van Winckel M, De Paepe P, Rogiers X, Stephenne X, Sokal E, Van Bocxlaer J. In vitro cytochrome p450 activity decreases in children with high pediatric end-stage liver disease scores. Drug Metab Dispos. 2013;41:390-397. [PMID: 23150427 DOI: 10.1124/dmd.112.048504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
203 Deal N, Hong M, Matorin A, Shah AA. Stabilization and Management of the Acutely Agitated or Psychotic Patient. Emergency Medicine Clinics of North America 2015;33:739-52. [DOI: 10.1016/j.emc.2015.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
204 Hulskotte EGJ, Feng H, Xuan F, van Zutven MGJA, Treitel MA, Hughes EA, O'mara E, Youngberg SP, Wagner JA, Butterton JR. Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. Clinical Infectious Diseases 2013;56:718-26. [DOI: 10.1093/cid/cis968] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
205 Yamamoto M, Yanagisawa R, Sakai A, Mogi M, Shuto S, Shudo M, Kashiwagi H, Kudo M, Nakamura M, Sakamoto M. Toxicokinetics of methylmercury in diabetic KK-Ay mice and C57BL/6 mice. J Appl Toxicol 2021;41:928-40. [PMID: 33015845 DOI: 10.1002/jat.4078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB. Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Mol Pharm 2019;16:4059-64. [PMID: 31393129 DOI: 10.1021/acs.molpharmaceut.9b00459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
207 Bahar MA, Wang Y, Bos JHJ, Wilffert B, Hak E. Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly. Pharmacoepidemiol Drug Saf 2018;27:621-9. [PMID: 29575226 DOI: 10.1002/pds.4422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
208 Howland RH. Down the hatch: is prescribing medication really that simple? J Psychosoc Nurs Ment Health Serv 2014;52:13-6. [PMID: 25004435 DOI: 10.3928/02793695-20140623-03] [Reference Citation Analysis]
209 Pedersen KW, Hansen J, Hasselstrøm JB, Jornil JR. Stability investigations of cytochrome P450 (CYP) enzymes immediately after death in a pig model support the applicability of postmortem hepatic CYP quantification. Pharmacol Res Perspect 2021;9:e00860. [PMID: 34478246 DOI: 10.1002/prp2.860] [Reference Citation Analysis]
210 Ng T, Chan A. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. Crit Rev Oncol Hematol 2012;81:58-74. [PMID: 21429761 DOI: 10.1016/j.critrevonc.2011.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
211 Steelandt J, Jean-Bart E, Goutelle S, Tod M. A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification. Clin Pharmacokinet 2015;54:1245-58. [PMID: 26070946 DOI: 10.1007/s40262-015-0288-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
212 Janković SM. Personalization of drug dose thematic issue: introduction article. Expert Opin Drug Metab Toxicol 2021;:1-5. [PMID: 34197236 DOI: 10.1080/17425255.2021.1951220] [Reference Citation Analysis]
213 Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis. American Journal of Health-System Pharmacy 2014;71:1621-34. [DOI: 10.2146/ajhp140031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
214 Sinha J, Duffull SB, Green B, Al-sallami HS. Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. Clin Pharmacokinet 2020;59:475-83. [DOI: 10.1007/s40262-019-00824-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
215 Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 2015;151:99-106. [PMID: 25805597 DOI: 10.1016/j.pharmthera.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
216 Triantafillidis JK, Merikas E, Nikolakis D, Papalois AE. Sedation in gastrointestinal endoscopy: Current issues. World J Gastroenterol 2013; 19(4): 463-481 [PMID: 23382625 DOI: 10.3748/wjg.v19.i4.463] [Cited by in CrossRef: 124] [Cited by in F6Publishing: 107] [Article Influence: 13.8] [Reference Citation Analysis]
217 Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. Eur J Pharm Sci 2013;49:836-44. [PMID: 23770377 DOI: 10.1016/j.ejps.2013.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
218 Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7:309-319. [PMID: 26864729 DOI: 10.1080/21505594.2016.1141162] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
219 García-Cortés M, García-García A. Management of Pharmacologic Adverse Effects in Advanced Liver Disease. Clin Drug Investig 2022. [PMID: 35522395 DOI: 10.1007/s40261-022-01150-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Itou M, Fujita T, Inoue K, Uchida N, Takagaki T, Ishii D, Kakuyama H. Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment. J Clin Pharmacol 2020;60:1397-403. [PMID: 32437025 DOI: 10.1002/jcph.1636] [Reference Citation Analysis]
221 Wada R, Takeuchi J, Nakamura T, Sonoyama T, Kosaka S, Matsumoto C, Sakuma M, Ohta Y, Morimoto T. Clinical Decision Support System with Renal Dose Adjustment Did Not Improve Subsequent Renal and Hepatic Function among Inpatients: The Japan Adverse Drug Event Study. Appl Clin Inform 2020;11:846-56. [PMID: 33368060 DOI: 10.1055/s-0040-1721056] [Reference Citation Analysis]
222 Ganesh S, Almazroo OA, Tevar A, Humar A, Venkataramanan R. Drug Metabolism, Drug Interactions, and Drug-Induced Liver Injury in Living Donor Liver Transplant Patients. Clin Liver Dis 2017;21:181-96. [PMID: 27842771 DOI: 10.1016/j.cld.2016.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
223 Bhatia G, Sarkar S. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations. Asian J Psychiatr 2020;53:102121. [PMID: 32460142 DOI: 10.1016/j.ajp.2020.102121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
224 Devlin JW, Barletta JF. Principles of Geriatric Pharmacotherapy. In: Akhtar S, Rosenbaum S, editors. Principles of Geriatric Critical Care. Cambridge University Press; 2018. pp. 28-50. [DOI: 10.1017/9781316676325.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 2018;78:1211-28. [PMID: 30051169 DOI: 10.1007/s40265-018-0953-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
226 Sanz Codina M, Zeitlinger M. Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review. Clin Pharmacokinet 2022. [PMID: 35218003 DOI: 10.1007/s40262-021-01102-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
227 Pirmohamed M. Prescribing in liver disease. Medicine 2015;43:577-80. [DOI: 10.1016/j.mpmed.2015.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Srinivas M. Cytochrome P450 Enzymes, Drug Transporters and their Role in Pharmacokinetic Drug-Drug Interactions of Xenobiotics: A Comprehensive Review. Open J Chem 2015. [DOI: 10.17352/ojc.000006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Lutwak N, Howland MA, Gambetta R, Dill C. Even 'safe' medications need to be administered with care. BMJ Case Rep 2013;2013:bcr2012006204. [PMID: 23283606 DOI: 10.1136/bcr-2012-006204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Chikhani M, Hardman JG. Pharmacokinetic variation. Anaesthesia & Intensive Care Medicine 2013;14:126-8. [DOI: 10.1016/j.mpaic.2013.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
231 Statkevich P, Kosoglou T, Preston RA, Kumar B, Xuan F, Trusley C, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur J Clin Pharmacol 2012;68:1501-8. [PMID: 22527342 DOI: 10.1007/s00228-012-1269-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
232 Ouwerkerk-mahadevan S, Halabi A, Cieslarová B, Aerts I, Witek J, Van Solingen-ristea R, Luo D. Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment. The Journal of Clinical Pharmacology 2015;55:1147-56. [DOI: 10.1002/jcph.545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
233 Sridharan K, Sannala CKR, Mallayasamy S, Chaturvedula A, Kadam P, Hase N, Shukla A, Gogtay N, Thatte U. Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach. Indian J Pharmacol 2019;51:17-24. [PMID: 31031463 DOI: 10.4103/ijp.IJP_230_16] [Reference Citation Analysis]
234 Halabi A, Maatouk H, Siegler KE, Faisst N, Hinrichsen H. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharmacol Drug Dev 2014;3:290-6. [PMID: 27128835 DOI: 10.1002/cpdd.89] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
235 Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol 2015;71:441-7. [DOI: 10.1007/s00228-015-1826-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
236 Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol 2018;15:168-80. [PMID: 29139482 DOI: 10.1038/nrgastro.2017.141] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 12.4] [Reference Citation Analysis]
237 Ono C, Hsyu P, Abbas R, Loi C, Yamazaki S. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions. Drug Metab Dispos 2017;45:390-8. [DOI: 10.1124/dmd.116.074450] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
238 Taegtmeyer AB, Haschke M, Tchambaz L, Buylaert M, Tschöpl M, Beuers U, Drewe J, Krähenbühl S. A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One 2014;9:e97885. [PMID: 24906133 DOI: 10.1371/journal.pone.0097885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
239 Chalabianloo F, Høiseth G, Vold JH, Johansson KA, Kringen MK, Dalgard O, Ohldieck C, Druckrey-Fiskaaen KT, Aas C, Løberg EM, Bramness JG, Fadnes LT. Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. J Addict Dis 2022;:1-11. [PMID: 35356868 DOI: 10.1080/10550887.2022.2057140] [Reference Citation Analysis]
240 Lombardi LR, Miano TA, Davis JL, Morgan SC, Goldstein SC, Vardhanabhuti S, Mitra N, Vozniak JM. A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients. J Oncol Pharm Pract 2012;18:3-9. [DOI: 10.1177/1078155210397963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
241 Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40:880-892. [PMID: 25175904 DOI: 10.1111/apt.12925] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 9.1] [Reference Citation Analysis]
242 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
243 Dasgupta A. Introduction to Therapeutic Drug Monitoring. Therapeutic Drug Monitoring. Elsevier; 2012. pp. 1-29. [DOI: 10.1016/b978-0-12-385467-4.00001-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
244 Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos 2015;43:1484-90. [DOI: 10.1124/dmd.115.065979] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
245 Hanna M. The effects of liver impairment on opioids used to relieve pain in cancer patients. Palliat Med 2011;25:604-5. [DOI: 10.1177/0269216311401642] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
246 Wilson A, Tirona RG, Kim RB. CYP3A4 Activity is Markedly Lower in Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:804-13. [DOI: 10.1097/mib.0000000000001062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol. 2014;61:139-147. [PMID: 24613363 DOI: 10.1016/j.jhep.2014.02.021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
248 Kaufmann P, Cruz HG, Krause A, Ulč I, Halabi A, Dingemanse J. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. Br J Clin Pharmacol 2016;82:369-79. [PMID: 27062188 DOI: 10.1111/bcp.12963] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
249 Newman KL, Johnson KM, Cornia PB, Wu P, Itani K, Ioannou GN. Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions. Clin Gastroenterol Hepatol 2020;18:2398-2414.e3. [PMID: 31376494 DOI: 10.1016/j.cgh.2019.07.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
250 Weisbach L, Schuster AK, Hartmann M, Fromm MF, Maas R, Farker K. Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications-A Systematic Analysis of SmPCs/PI of Major Drug Markets. J Clin Med 2022;11:1933. [PMID: 35407541 DOI: 10.3390/jcm11071933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Sun X, Tang S, Hou B, Duan Z, Liu Z, Li Y, He S, Wang Q, Chang Q. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension. BMC Gastroenterol 2021;21:2. [PMID: 33407159 DOI: 10.1186/s12876-020-01532-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
252 Currow DC, Phillips JL. Chronic Conditions and Cancer at the End of Life. In: Koczwara B, editor. Cancer and Chronic Conditions. Singapore: Springer; 2016. pp. 455-75. [DOI: 10.1007/978-981-10-1844-2_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
253 Moorehead KJ, Burton JR Jr, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ. Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. J Antimicrob Chemother 2015;70:315-7. [PMID: 25213274 DOI: 10.1093/jac/dku334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
254 Sun L, Barter Z, von Moltke L, Rowland Yeo K. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34185436 DOI: 10.1002/psp4.12675] [Reference Citation Analysis]
255 Song IH, Borland J, Savina PM, Chen S, Patel P, Wajima T, Peppercorn AF, Piscitelli SC. Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls. Clin Pharmacol Drug Dev 2013;2:342-8. [PMID: 26097786 DOI: 10.1002/cpdd.55] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
256 Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013;108:21-24. [PMID: 23287988 DOI: 10.1038/bjc.2012.556] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
257 Albiges L, Gizzi M, Carton E, Escudier B. Axitinib in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 2015;15:499-507. [DOI: 10.1586/14737140.2015.1033408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
258 Höcht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opinion on Drug Metabolism & Toxicology 2010;6:199-211. [DOI: 10.1517/17425250903397381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
259 Regal RE, Ren SP, Paige G, Alaniz C. Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De-Liver-ations about a New Nomogram. Hosp Pharm 2019;54:125-9. [PMID: 30923406 DOI: 10.1177/0018578718772266] [Reference Citation Analysis]
260 Fang Z, Zhang Y, Wang X, Cao Y, Huo H, Yang L. Bioactivation of herbal constituents: simple alerts in the complex system. Expert Opinion on Drug Metabolism & Toxicology 2011;7:989-1007. [DOI: 10.1517/17425255.2011.586335] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
261 Lucas CJ, Patel J, Martin JH. Predicting drug interactions in addiction treatment. Intern Med J 2017;47:872-8. [PMID: 28782217 DOI: 10.1111/imj.13500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. J Clin Pharmacol 2019;59:1204-15. [PMID: 30985952 DOI: 10.1002/jcph.1416] [Reference Citation Analysis]
263 Nagata M, Hidaka Y, Hatakeyama K, Kawano Y, Iwakiri T, Okumura M, Arimori K. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats. Biopharm Drug Dispos 2011;32:126-30. [DOI: 10.1002/bdd.744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
264 Khalilieh S, Yee KL, Sanchez R, Stoch SA, Wenning L, Iwamoto M. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. Clin Drug Investig 2020;40:927-46. [PMID: 32816220 DOI: 10.1007/s40261-020-00934-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
265 Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol 2013;69:1565-73. [DOI: 10.1007/s00228-013-1502-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
266 Yogaratnam D, Ditch K, Medeiros K, Miller MA, Smith BS. The Impact of Liver and Renal Dysfunction on the Pharmacokinetics and Pharmacodynamics of Sedative and Analgesic Drugs in Critically Ill Adult Patients. Crit Care Nurs Clin North Am 2016;28:183-94. [PMID: 27215356 DOI: 10.1016/j.cnc.2016.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol 2021;21:120. [PMID: 33726685 DOI: 10.1186/s12876-021-01704-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Su M, Chen H, Wei C, Chen N, Wu W. Potential protection of vitamin C against liver-lesioned mice. Int Immunopharmacol. 2014;22:492-497. [PMID: 25116224 DOI: 10.1016/j.intimp.2014.07.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
269 Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet 2019;44:619-28. [DOI: 10.1007/s13318-019-00547-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
270 Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'bryant CL, El‐rayes BF, Chung V, Lenz H, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol 2019;85:2499-511. [DOI: 10.1111/bcp.14054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
271 Behan J, Geier M. Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: A case report. Ment Health Clin 2016;6:131-3. [PMID: 29955460 DOI: 10.9740/mhc.2016.05.131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
272 Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res. 2013;37 Suppl 1:E17-E22. [PMID: 22827451 DOI: 10.1111/j.1530-0277.2012.01901.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
273 Rashid M, Sarfraz M, Arafat M, Hussain A, Abbas N, Sadiq MW, Rasool MF, Bukhari NI. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. BMC Pharmacol Toxicol 2020;21:56. [PMID: 32727574 DOI: 10.1186/s40360-020-00429-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
274 Kurata A, Yoshida T, Inoue M, Ishizuka T, Nakatsu T, Shimizu T, Kato M, Nishikawa Y, Ishizuka H. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment. Adv Ther 2020;37:253-64. [PMID: 31705436 DOI: 10.1007/s12325-019-01121-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
275 Mosedale M, Watkins PB. Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. J Med Chem 2020;63:6436-61. [PMID: 32037821 DOI: 10.1021/acs.jmedchem.9b01297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
276 Katsube T, Shimizu R, Fukuhara T, Kano T, Wajima T. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clin Pharmacokinet 2019;58:1469-82. [PMID: 31055790 DOI: 10.1007/s40262-019-00770-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
277 Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet 2014;53:1069-81. [PMID: 25248846 DOI: 10.1007/s40262-014-0187-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
278 Uji M, Yokoyama Y, Ohbuchi K, Tsuchiya K, Sadakane C, Shimobori C, Yamamoto M, Nagino M. Exploration of serum biomarkers for predicting the response to Inchinkoto (ICKT), a Japanese traditional herbal medicine. Metabolomics 2017;13:155. [PMID: 31375927 DOI: 10.1007/s11306-017-1292-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
279 Ikemura M, Nakagawa Y, Shinone K, Inoue H, Nata M. The blood concentration and organ distribution of haloperidol at therapeutic and toxic doses in severe fatty liver disease. Leg Med (Tokyo) 2012;14:147-53. [PMID: 22366175 DOI: 10.1016/j.legalmed.2012.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
280 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, Taxis K, Borgsteede SD. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf 2018;41:603-13. [PMID: 29330714 DOI: 10.1007/s40264-017-0635-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
281 Chikhani M, Hardman JG. Pharmacokinetic variation. Anaesthesia & Intensive Care Medicine 2011;12:368-70. [DOI: 10.1016/j.mpaic.2011.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
282 Nishizawa K, Yoda N, Morokado F, Komori H, Nakanishi T, Tamai I. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. PLoS One 2019;14:e0214862. [PMID: 30951542 DOI: 10.1371/journal.pone.0214862] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
283 Delord JP, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel MC, Ferré P, Saliba F. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs 2013;31:724-33. [DOI: 10.1007/s10637-012-9878-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
284 Sparkes AH, Heiene R, Lascelles BDX, Malik R, Real L, Robertson S, Scherk M, Taylor P. ISFM and AAFP Consensus Guidelines: Long-Term use of NSAIDs in Cats. Journal of Feline Medicine and Surgery 2010;12:521-38. [DOI: 10.1016/j.jfms.2010.05.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
285 Wicha SG, Frey OR, Roehr AC, Pratschke J, Stockmann M, Alraish R, Wuensch T, Kaffarnik M. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. Int J Antimicrob Agents 2017;50:557-63. [PMID: 28711678 DOI: 10.1016/j.ijantimicag.2017.06.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
286 Yardley DA. Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists. Clinical Breast Cancer 2014;14:297-308. [DOI: 10.1016/j.clbc.2014.03.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
287 Markowitz JS. Transforming events: hepatic metabolism and individual variability. Clin Ther 2013;35:202-4. [PMID: 23497758 DOI: 10.1016/j.clinthera.2013.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
288 Parikh JM, Amolenda P, Rutledge J, Szabova A, Chidambaran V. An update on the safety of prescribing opioids in pediatrics. Expert Opin Drug Saf 2019;18:127-43. [PMID: 30650988 DOI: 10.1080/14740338.2019.1571037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
289 Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol. 2014;10:839-857. [PMID: 24669954 DOI: 10.1517/17425255.2014.902444] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
290 Sharma P. Value of Liver Function Tests in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.004] [Reference Citation Analysis]
291 Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol 2016;72:905-16. [PMID: 27305904 DOI: 10.1007/s00228-016-2083-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
292 Haanpää ML, Gourlay GK, Kent JL, Miaskowski C, Raja SN, Schmader KE, Wells CD. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010;85:S15-25. [PMID: 20194144 DOI: 10.4065/mcp.2009.0645] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
293 Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol 2016;82:728-38. [PMID: 27121262 DOI: 10.1111/bcp.12991] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
294 Ho HK, Chan JC, Hardy KD, Chan EC. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev 2015;47:21-8. [PMID: 25639891 DOI: 10.3109/03602532.2014.1003648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
295 Hughes LT, Raftery D, Coulter P, Laird B, Fallon M. Use of opioids in patients with cancer with hepatic impairment-a systematic review. BMJ Support Palliat Care 2021:bmjspcare-2021-003065. [PMID: 34470772 DOI: 10.1136/bmjspcare-2021-003065] [Reference Citation Analysis]
296 Boivin P, Legendre P, Bonnaure A, Lester M. Physicochemical stability of compounded midazolam capsules over a one-year storage period. Pharmaceutical Technology in Hospital Pharmacy 2020;5:20200015. [DOI: 10.1515/pthp-2020-0015] [Reference Citation Analysis]
297 Li Z, Gan L, Marbury T, Lasseter KC, Natarajan A, Stecher S, Wei D, Yang L, Freedman D, Deykin A. Pharmacokinetics of Oral Tonapofylline and Its Acyl-Glucuronide Metabolite in Patients With Mild and Moderate Hepatic Impairment. The Journal of Clinical Pharmacology 2012;52:543-51. [DOI: 10.1177/0091270011400413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Crass RL, Pai MP. Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. Clin Pharmacokinet 2019;58:1323-32. [PMID: 30972695 DOI: 10.1007/s40262-019-00761-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
299 Mesotten D, Wauters J, Van den Berghe G, Wouters PJ, Milants I, Wilmer A. The Effect of Strict Blood Glucose Control on Biliary Sludge and Cholestasis in Critically Ill Patients. The Journal of Clinical Endocrinology & Metabolism 2009;94:2345-52. [DOI: 10.1210/jc.2008-2579] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
300 Kaburaki S, Yoshimura E, Miyamoto Y, Imai S, Kashiwagi H, Ueno H, Sugawara M, Takekuma Y. Hepatic drug metabolism in older people with body composition changes. Geriatr Gerontol Int 2022;22:449-54. [PMID: 35355383 DOI: 10.1111/ggi.14380] [Reference Citation Analysis]
301 Nguyen HM, Cutie AJ, Pham DQ. How to manage medications in the setting of liver disease with the application of six questions: Managing medications in liver disease. International Journal of Clinical Practice 2010;64:858-67. [DOI: 10.1111/j.1742-1241.2010.02364.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
302 Chen X, Cui X, Pognan N, Quinlan M, Kapoor S, Rahmanzadeh G, Giovannini M, Marbury TC. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study. Br J Clin Pharmacol 2021. [PMID: 34046915 DOI: 10.1111/bcp.14929] [Reference Citation Analysis]
303 Li X, Luthra R, Morrow PK, Fisher MD, Reiner M, Barron RL, Langeberg WJ. Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle. J Oncol Pharm Pract 2016;22:679-89. [PMID: 26378158 DOI: 10.1177/1078155215603229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
304 El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther 2021;54:388-401. [PMID: 34218453 DOI: 10.1111/apt.16489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
305 Tortorici MA, Toh M, Rahavendran SV, Labadie RR, Alvey CW, Marbury T, Fuentes E, Green M, Ni G, Hee B, Pithavala YK. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011;29:1370-80. [PMID: 20596748 DOI: 10.1007/s10637-010-9477-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
306 Vuppalanchi R, Liang T, Goswami CP, Nalamasu R, Li L, Jones D, Wei R, Liu W, Sarasani V, Janga SC. Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One. 2013;8:e74471. [PMID: 24058572 DOI: 10.1371/journal.pone.0074471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
307 Tan JL, Eastment JG, Poudel A, Hubbard RE. Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. Drugs Aging 2015;32:999-1008. [DOI: 10.1007/s40266-015-0318-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
308 Mckeand W, Baird-bellaire S, Ermer J, Patat A. Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women. Clinical Pharmacology in Drug Development 2018;7:365-72. [DOI: 10.1002/cpdd.438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
309 Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer Chemother Pharmacol 2020;85:1109-17. [PMID: 32449142 DOI: 10.1007/s00280-020-04084-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Venuto CS, Talal AH. Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. Clin Pharmacol Drug Dev 2017;6:169-75. [PMID: 28263459 DOI: 10.1002/cpdd.311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
311 Csonka D, Hazell K, Waldron E, Lorenzo S, Duval V, Trandafir L, Kobalava ZD. A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. J Clin Pharmacol 2016;56:316-23. [PMID: 26183800 DOI: 10.1002/jcph.590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
312 Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2014;16:118-123. [PMID: 23859534 DOI: 10.1111/dom.12183] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
313 Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krähenbühl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet 2021. [PMID: 34002356 DOI: 10.1007/s40262-021-01028-8] [Reference Citation Analysis]
314 Bessada SM, Alves RC, Oliveira MBP. Caffeine-based food supplements and beverages: Trends of consumption for performance purposes and safety concerns. Food Research International 2018;109:310-9. [DOI: 10.1016/j.foodres.2018.04.050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
315 Guérard N, Zwingelstein C, Hoch M, Dingemanse J. Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P 1 Receptor Modulator. Basic Clin Pharmacol Toxicol 2016;118:356-68. [DOI: 10.1111/bcpt.12516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
316 Shah SR, Tatara AM, Lam J, Lu S, Scott DW, Bennett GN, van den Beucken JJJP, Jansen JA, Wong ME, Mikos AG. Polymer-Based Local Antibiotic Delivery for Prevention of Polymicrobial Infection in Contaminated Mandibular Implants. ACS Biomater Sci Eng 2016;2:558-66. [DOI: 10.1021/acsbiomaterials.5b00545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
317 Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G. Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment. J Clin Pharmacol 2012;52:1714-24. [PMID: 22162535 DOI: 10.1177/0091270011426143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
318 Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132-1156. [PMID: 23638982 DOI: 10.1111/apt.12324] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 13.3] [Reference Citation Analysis]
319 Gonzalez M, Goracci L, Cruciani G, Poggesi I. Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on Drug Metabolism & Toxicology 2014;10:1397-408. [DOI: 10.1517/17425255.2014.952628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
320 McNeill RP, Zhang M, Epton MJ, Doogue MP. Drug metabolism in severe chronic obstructive pulmonary disease: A phenotyping cocktail study. Br J Clin Pharmacol 2021. [PMID: 33855722 DOI: 10.1111/bcp.14862] [Reference Citation Analysis]
321 DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis. 2014;37:217-233. [PMID: 23860880 DOI: 10.1007/s11239-013-0967-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
322 Angamo MT, Chalmers L, Curtain CM, Yilma D, Bereznicki L. Mortality from adverse drug reaction-related hospitalizations in south-west Ethiopia: A cross-sectional study. J Clin Pharm Ther 2018;43:790-8. [PMID: 29722039 DOI: 10.1111/jcpt.12702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
323 Izrailtyan I, Qiu J, Overdyk FJ, Erslon M, Gan TJ. Risk factors for cardiopulmonary and respiratory arrest in medical and surgical hospital patients on opioid analgesics and sedatives. PLoS One 2018;13:e0194553. [PMID: 29566020 DOI: 10.1371/journal.pone.0194553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
324 Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, Höcht C. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn-Schmiedeberg's Arch Pharmacol 2012;385:325-35. [DOI: 10.1007/s00210-011-0698-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
325 Weersink RA, Taxis K, Drenth JPH, Houben E, Metselaar HJ, Borgsteede SD. Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study. Drug Saf 2019;42:539-46. [PMID: 30357649 DOI: 10.1007/s40264-018-0744-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
326 Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76:89-98. [PMID: 23294275 DOI: 10.1111/bcp.12054] [Cited by in Crossref: 105] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
327 Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother 2019:AAC. [PMID: 31591118 DOI: 10.1128/AAC.01215-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
328 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
329 Giri N, Masters JC, Plotka A, Liang Y, Boutros T, Pardo P, O'Connell J, Bello C. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs 2015;33:931-41. [PMID: 26048096 DOI: 10.1007/s10637-015-0256-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
330 Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ. Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther 2015;13:799-815. [PMID: 25947367 DOI: 10.1586/14787210.2015.1028366] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
331 Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H. Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin. Clin Drug Investig 2018;38:1001-9. [PMID: 30171457 DOI: 10.1007/s40261-018-0692-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
332 Case AA, Kullgren J, Anwar S, Pedraza S, Davis MP. Treating Chronic Pain with Buprenorphine-The Practical Guide. Curr Treat Options Oncol 2021;22:116. [PMID: 34791564 DOI: 10.1007/s11864-021-00910-8] [Reference Citation Analysis]
333 Musgrave IF, Farrington RL, Hoban C, Byard RW. Caffeine toxicity in forensic practice: possible effects and under-appreciated sources. Forensic Sci Med Pathol 2016;12:299-303. [PMID: 27344159 DOI: 10.1007/s12024-016-9786-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
334 Burris JF, Tortorici MA, Mandic M, Neely M, Reed MD. Dosage Adjustments Related to Young or Old Age and Organ Impairment. J Clin Pharmacol 2016;56:1461-73. [PMID: 27539787 DOI: 10.1002/jcph.816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
335 Mücke MM, Mücke VT, Lange CM, Zeuzem S. Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. Liver Int 2017;37 Suppl 1:19-25. [PMID: 28052635 DOI: 10.1111/liv.13279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
336 Amatniek J, Canuso CM, Deutsch SI, Henderson DC, Mao L, Mikesell C, Rodriguez S, Sheehan J, Alphs L. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease. Clin Schizophr Relat Psychoses 2014;8:8-20. [PMID: 23428785 DOI: 10.3371/CSRP.AMCA.021513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
337 Salman B, Al-Khabori M. Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. J Oncol Pharm Pract 2021;27:693-701. [PMID: 33302823 DOI: 10.1177/1078155220979048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]